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Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal homeostasis, and are
often associated with abnormal circulating concentrations of calcium, phosphate or vitamin D metabolites. These diseases
commonly have a genetic basis and represent either a monogenic disorder due to a germline or somatic single gene mutation,
or an oligogenic or polygenic disorder that involves variants in more than one gene. Germline single gene mutations causing
Mendelian diseases typically have a high penetrance, whereas the genetic variations causing oligogenic or polygenic disorders
are each associated with smaller effects with additional contributions from environmental factors. Recognition of familial
monogenic disorders is of clinical importance to facilitate timely investigations and management of the patient and any
affected relatives. The diagnosis of monogenic metabolic bone disease requires careful clinical evaluation of the large diversity
of symptoms and signs associated with these disorders. Thus, the clinician must pursue a systematic approach beginning with
a detailed history and physical examination, followed by appropriate laboratory and skeletal imaging evaluations. Finally, the
clinician must understand the increasing number and complexity of molecular genetic tests available to ensure their
appropriate use and interpretation.

Introduction
Metabolic bone diseases represent a diverse group of skeletal
conditions characterized by alterations in bone cell activity,
bone matrix proteins or systemic mineral homeostasis
(Table 1) [1, 2]. Many metabolic bone diseases have a genetic
basis, which may be a germline single gene abnormality
(i.e. a monogenic or Mendelian disorder), a somatic single
gene defect (i.e. a post-zygotic mosaic disorder) or involve
several genetic variants (i.e. oligogenic or polygenic disorders) [3]. Genetic mutations causing Mendelian diseases

usually have a large effect (i.e. penetrance), whereas
oligogenic or polygenic disorders are associated with several
genetic variations, each of which may have smaller effects
with greater or smaller contributions from environmental
factors (i.e. multifactorial disorders) [3]. Whilst many monogenic disorders result from rare mutations affecting the coding sequence of the responsible gene, the majority of
common genetic variants identiﬁed in association with
polygenic traits are located in non-coding regions, usually
in proximity to candidate genes implicated in the respective
disorders [4]. Furthermore, there is substantial overlap
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Table 1
Examples of monogenic metabolic bone disorders, modes of inheritance and genetic aetiology

Mode of inheritance/Disease

Gene(s)

Chromosomal location

References

Osteogenesis imperfecta (OI), types I-IV

COL1A1, COL1A2

17q21.33, 7q21.3

[20]

Osteogenesis imperfecta (OI), type V

IFITM5

11p15.5

[23, 24]

Autosomal dominant hypophosphataemic rickets

FGF23

12p13.32

[25]

Autosomal dominant high bone mass, type 1

LRP5

11q13.2

[47]

Autosomal dominant high bone mass, type 2

LRP6

12p13.2

[48]

Early-onset osteoporosis

WNT1

12q13.12

[19]

Familial hypocalciuric hypercalcaemia (FHH), types 1–3

CASR, GNA11, AP2S1

3q21.1, 19p13.3, 19q13.3

[31–33]

Autosomal dominant hypocalcaemia (ADH), types 1–2

CASR, GNA11

3q21.1, 19p13.3

[32, 37]

Familial expansile osteolysis

TNFRSF11A

18q21.33

[34, 35]

Hypophosphatasia

TNSALP/ALPL

1p36.12

[36]

CYP3A4

7q22.1

[88]

GNAS

20q13.3

[39]

GNAS

20q13.3

[39]

GNAS, NESP55, STX16

20q13.3

[39]

Osteogenesis imperfecta (OI), type VI

SERPINF1

17p13.3

[106]

Osteogenesis imperfecta (OI), type VII

CRTAP

3p22.3

[21]

Osteogenesis imperfecta (OI), type VIII

P3H1/LEPRE1

1p34.2

[107]

Osteogenesis imperfecta (OI), type XV

WNT1

12q13.12

[19]

Hypophosphatasia

TNSALP/ALPL

1p36.12

[36]

Neonatal severe hyperparathyroidism (NSHPT)

CASR

3q21.1

[31]

Vitamin D-dependent rickets, type 1

CYP27B1

12q14.1

[10]

Vitamin D-dependent rickets, type 2

VDR

12q13.11

[10]

Autosomal recessive hypophosphataemic rickets

DMP1, ENPP1

4q22.1, 6q23.2

[27, 28]

Hereditary hypophosphataemic rickets with hypercalciuria

SLC34A3

9q34.3

[29, 30]

Autosomal dominant

Vitamin D-dependent rickets, type 3
Pseudohypoparathyroidism, type 1a (PHP1a)

a

Pseudopseudohypoparathyroidism (PPHP)a
Pseudohypoparathyroidism, type 1b (PHP1b)

a

Autosomal recessive

Osteoporosis-pseudoglioma syndrome

LRP5

11q13.2

[46]

Sclerosteosis, type 1

SOST

17q21.31

[49]

Sclerosteosis, type 2

LRP4

11p11.2

[50]

Pyle’s disease

SFRP4

7p14.1

[54]

Juvenile Paget disease

TNFRSF11B

8q24.12

[108]

PHEX

Xp22.11

[26]

X-linked osteoporosis

PLS3

Xq23

[18]

Dent disease, type 1

CLCN5

Xp11.23

[11]

X-linked dominant
X-linked hypophosphatemic (XLH) rickets
X-linked recessive

(continues)
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Table 1
(Continued)

Mode of inheritance/Disease

Gene(s)

Chromosomal location

References

Mitochondrial encephalomyopathy with lactic acidosis
and stoke-like episodes (MELAS)

Mitochondrial genome

-

[13]

Kearns-Sayre syndrome

Mitochondrial genome

-

[14]

GNAS

20q13.3

[15]

COL1A1/COL1A2

17q21.33, 7q21.3

Mitochondrial

Mosaicism
McCune-Albright syndrome (polyostotic ﬁbrous dysplasia)a
Osteogenesis imperfecta (OI)

b

a

Parentally imprinted
Autosomal disorder manifesting as post-zygotic somatic mosaicism in the developing fetus, or arising from germline mosaicism in an apparently
unaffected parent
b

between the genes responsible for monogenic skeletal diseases and those contributing to polygenic bone phenotypes.
The elucidation of these loci has provided insights into the
molecular pathogenesis of skeletal disease, and highlighted
novel therapeutic targets [5–7]. This review discusses the genetics of metabolic bone diseases, and outlines the clinical
and genetic approach to evaluating these disorders.

Genetics of metabolic bone diseases
Inheritance
Metabolic bone diseases may be caused by single-gene
mutations or represent digenic or complex polygenic traits
[1, 3, 8]. Inheritance of monogenic diseases occurs as one of
six traits: autosomal dominant [e.g. familial hypocalciuric
hypercalcaemia (FHH) due to mutations of the calciumsensing receptor (CaS receptor) signalling pathway [9]];
autosomal recessive [e.g. vitamin D-dependent rickets types 1
and 2 from mutations of the renal 1α-hydroxylase (CYP27B1)
and vitamin D receptor (VDR) genes, respectively [10]];
X-linked recessive [e.g. Dent’s disease involving chloride
channel 5 (CLC-5) [11]]; X-linked dominant [e.g. X-linked
hypophosphataemic (XLH) rickets from mutations of a
phosphate endopeptidase on the X chromosome (PHEX)
gene [10]]; Y-linked (e.g. azoospermia and oligospermia)
[12]; and non-Mendelian mitochondrial defects [e.g. hypoparathyroidism in Kearns-Sayre syndrome and mitochondrial encephalopathy, lactic acidosis and stroke-like episodes
(MELAS) syndrome] [13, 14]. Monogenic metabolic bone
diseases may also be caused by sporadic postzygotic mosaicism [e.g. McCune-Albright syndrome (MAS)] (Table 1) [15].
Digenic inheritance has been reported in a family with
hereditary hypophosphataemic rickets with hypercalciuria
(HHRH), who harbour heterozygous mutations of the
SLC34A1 and SLC34A3 genes, encoding the renal sodiumphosphate co-transporters type 2a and 2c, respectively [8].
The major metabolic bone disorder representing a complex
polygenic trait is osteoporosis, and more than 200 loci have
been associated with this common disorder [16, 17]. However, the majority of loci for osteoporosis likely remain to be

elucidated. Osteoporosis may rarely occur as a monogenic
condition, e.g. X-linked osteoporosis due to mutations of
the Plastin 3 (PLS3) gene [18], or early-onset osteoporosis
due to heterozygous mutations of the Wnt family member 1
(WNT1) gene (Table 1) [19].

Genetic heterogeneity
Many phenotypically similar metabolic bone disorders are
caused by mutations in a variety of different genes. For
example, 85–90% of osteogenesis imperfecta (OI) cases are
due to mutations in the genes encoding type 1 collagen
(i.e. COL1A1 and COL1A2) [20], with the remaining 10–15%
of OI cases being caused by mutations affecting genes involved
in post-translational processing of collagen [e.g. cartilageassociated protein (CRTAP)] [21], osteoblast differentiation
and function (e.g. WNT1) [19, 22], or bone mineralization
[e.g. interferon-induced transmembrane protein 5 (IFITM5)]
(Table 1) [23, 24]. Similarly, hypophosphataemic rickets may
be caused by mutations of genes encoding phosphatonins
like ﬁbroblast growth factor-23 (FGF-23), or osteoblast and
osteocyte proteins that mediate the expression and secretion
of FGF-23 [e.g. PHEX, dentin matrix protein 1 (DMP1), and
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1)]
[25–28], or by mutations affecting renal sodium phosphate
co-transporters (e.g. SLC34A3) (Table 1) [29, 30]. In addition,
FHH, which is a disorder of extracellular calcium homeostasis,
has been shown to comprise three types, which are caused by
germline loss-of-function mutations affecting the CaS receptor,
G-protein subunit-α11 (Gα11), and adaptor-related protein
complex-2 σ-subunit (AP2σ), respectively (Table 1) [31–33].
Mutations within a single gene may give rise to seemingly
distinctive skeletal phenotypes [(e.g. familial expansile
osteolysis (FEO), expansile skeletal hyperphosphatasia (ESH)
and early-onset familial Paget’s disease of bone (PDB)], which
are rapid remodelling skeletal disorders arising from mutations in the signal peptide of receptor activator of NF-κB
(RANK) [34, 35]. In some metabolic bone diseases, the severity may be determined by mutant allele dosage and whether a
mutation is carried in the heterozygous or homozygous state.
For example, the severe perinatal and infantile forms of
hypophosphatasia, an inborn-error-of-metabolism characterized by alkaline phosphatase (ALP) deﬁciency, are inherited
Br J Clin Pharmacol (2019) 85 1147–1160
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in an autosomal recessive manner, whilst later-onset and
milder forms are typically inherited in an autosomal dominant fashion (Table 1) [36]. Moreover, some disorders of mineral metabolism are caused by loss- or gain-of-function
mutations affecting the same gene. Thus, loss-of-function
CaS receptor mutations cause FHH or neonatal severe hyperparathyroidism (NSHPT), whereas gain-of-function CaS receptor mutations cause autosomal dominant hypocalcaemia
(ADH) or Bartter syndrome type V [31, 37, 38]. Furthermore,
parental imprinting, which results in non-Mendelian
inheritance of a monogenic disorder, may inﬂuence the phenotypic consequences of a speciﬁc mutation. For example,
maternally-inherited inactivating coding-region mutations
of G-protein subunit αs (Gαs), which is encoded by the GNAS
gene, cause pseudohypoparathyroidism type 1a (PHP1a),
which is characterized by PTH resistance together with
Albright’s hereditary osteodystrophy (AHO) [39]; whereas,
paternally-inherited inactivating coding-region GNAS
mutations cause pseudopseudohypoparathyroidism (PPHP),
which is characterized by AHO without PTH resistance
(Table 1) [39]. The phenotype of MAS, which is caused by somatic activating Gαs mutations, is also dependent on parental imprinting, with acromegaly occurring in MAS patients
who harbour mutations affecting the maternal Gαs allele
[40]. Given this apparent genetic/phenotypic complexity despite genetic ‘homogeneity’, establishing the genetic cause
can be challenging for the evaluation of patients and family
members with bone and mineral disorders.

Molecular insights from monogenic and
polygenic diseases
Classical gene discovery approaches for monogenic disorders have involved studying affected kindreds for cosegregation with polymorphic genetic markers to deﬁne
the chromosomal location, followed by DNA sequence analysis of genes located within the candidate region [3]. This
approach has been superseded by whole-exome and
whole-genome sequence analysis of affected patients or kindreds [41, 42]. In contrast, the genetic investigation of complex polygenic disorders such as osteoporosis has utilized
genome-wide association studies (GWAS), which involve
large populations of cases and controls [5, 6, 16, 17]. Such
studies typically involve direct or imputed genotyping of
large numbers of common (e.g. minor allele frequency
>5%) and infrequent (e.g. minor allele frequency 1–5%)
single nucleotide polymorphisms/variants (SNPs/SNVs) to
identify genetic loci enriched for the trait [3, 43]. The genetic
investigation of monogenic diseases has provided a fundamental understanding of the molecular regulation of bone
mass and maintenance of skeletal microarchitecture. For example, studies of mutations affecting several Wnt pathway
components have demonstrated that Wnt signalling plays a
key anabolic role in the skeleton (Figure 1) [44, 45]. Thus,
autosomal-recessive loss-of-function mutations of the LRP5
gene, which encodes a key Wnt co-receptor (Figure 1), result
in osteoporosis-pseudoglioma syndrome, which is characterized by severe juvenile osteoporosis and congenital or
childhood-onset blindness [46]. In contrast, heterozygous activating mutations in LRP5 [47] and LRP6 [48], which encode
the cognate co-receptors LRP5 and LRP6, respectively, both
1150
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lead to autosomal dominant high bone mass. Additionally,
individuals with autosomal recessive loss-of-function mutations of the Wnt-β-catenin inhibitor sclerostin (SOST) manifest sclerosteosis, type 1, which is characterized by
progressive bone overgrowth throughout life [49, 50]; whilst
patients harbouring a homozygous 52 kb deletion containing
an enhancer element downstream of the SOST gene develop
van Buchem disease, which has a similar but milder skeletal
phenotype compared to sclerosteosis, type 1 [51, 52]. Moreover, bi-allelic loss-of-function mutations of WNT1 have
been shown to cause an autosomal recessive form of OI, whilst
heterozygous carriers of such WNT1 missense mutations develop autosomal dominant early-onset osteoporosis (Figure 1)
[19, 53]. Additionally, bi-allelic truncating mutations in
secreted frizzled-related protein 4 (sFRP-4) (Figure 1), which
encodes a soluble Wnt inhibitor, have been reported in
patients with Pyle’s disease, a disorder characterized by cortical bone thinning, limb deformity and fracture [54]. These
key roles for Wnt signalling in bone biology are supported
by the ﬁndings from GWAS studies, which have identiﬁed
that many Wnt pathway components (>15 genes), including LRP5 and SOST, are candidate genes for bone mineral
density (BMD) [16, 17], and that WNT16 is a key determinant of cortical bone strength [55, 56].

Application of genetic discoveries to the
development of targeted therapies
A key aim of the genetic characterization of metabolic bone
disorders has been to identify genes, molecules and pathways
that may be targeted therapeutically. Thus, the identiﬁcation
of the bone cell OPG/RANKL/RANK/NF-κB signalling
pathway led to the development of the monoclonal antibody denosumab, which blocks RANK ligand (RANKL),
thereby inhibiting osteoclast-mediated bone resorption [5].
Denosumab is now widely used for the treatment of osteoporosis as it signiﬁcantly reduces fracture risk in women
with postmenopausal osteoporosis [57]. The multinational
approval in 2015 of the bone-targeted enzyme-replacement
biologic asfotase alfa to treat hypophosphatasia has emphasized the importance of determining the genetic and molecular basis for a metabolic bone disease [36]. The
identiﬁcation that PHEX mutations cause FGF-23 excess,
which in turn is responsible for the phosphate wasting in
XLH [58, 59], has led to the approval in 2018 of
burosumab, which is an anti-FGF-23 monoclonal antibody, for the treatment of XLH rickets. Burosumab has been
shown to improve serum phosphate concentrations and decrease the severity of rickets in children with XLH [60].
Assessing treatment response according to the genetic
aetiology has been investigated in patients with early-onset
low-turnover osteoporosis due to WNT1 or PLS3 mutations
who were shown to respond to teriparatide therapy [61].
Now, several drugs in development are directed at the Wnt
pathway. This includes anti-sclerostin antibodies (e.g.
romosozumab), which increase bone formation whilst
inhibiting bone resorption [62]. An evaluation of
romosozumab in phase 3 clinical trials has shown that it is
a potent bone anabolic agent for postmenopausal osteoporosis [63, 64].

Genetic approaches to metabolic bone diseases

Figure 1
Schematic representation of Wnt signalling pathway components reported to be mutated in disorders of bone development and skeletal homeostasis. Activation of the canonical Wnt pathway increases bone mass, and this is mediated by the binding of extracellular Wnt ligands (dark green)
to a transmembrane receptor complex comprising the Wnt co-receptor LRP5 or LRP6 (LRP5/6, light blue) and a member of the frizzled (FZD) family (dark blue). In contrast, inhibition of the canonical Wnt pathway decreases bone mass [44, 45]. This inhibition is mediated by extracellular factors such as sclerostin (SOST, orange) and Dickkopf-related protein 1 (DKK1, yellow), which bind to the LRP5/6 co-receptor thereby preventing
activation by Wnt ligands, as well as recruiting inhibitory transmembrane proteins such as LRP4, which is a SOST-interacting protein (light green),
and the Kremen proteins (pink), which are high-afﬁnity DKK1 receptors that functionally cooperate with DKK1 to decrease Wnt signalling [109].
Secreted-frizzled-related proteins (SFRPs, purple) also inhibit the canonical Wnt pathway by sequestering Wnt ligands. The importance of the
canonical Wnt pathway for the regulation of bone mass has been highlighted by loss-of-function mutations affecting SOST and LRP4, and by
gain-of-function mutations of LRP5 and LRP6, which lead to the disorder called high bone mass [47, 49, 51, 110]; and also by loss-of-function
mutations of LRP5 and the Wnt1 ligand, which lead to monogenic osteoporosis disorders [19, 46]

Clinical approach to the patient with a
metabolic bone disease
Medical history and physical examination
The diagnosis of genetic forms of metabolic bone diseases begins by acquiring information from the patient’s medical history and physical examination [3]. The ‘history of present
illness’ provides critical clues concerning aetiology, pathogenesis and prognosis, as well as guiding diagnosis and therapy. Establishing whether the signs and symptoms have
been lifelong or begun recently may prompt different diagnostic considerations and interventions. Thus, lifelong
fractures which have occurred following minor trauma may
suggest a diagnosis of OI [20], whereas the combined

occurrence of fractures and renal calculi in early adulthood
may potentially be a presenting feature of primary hyperparathyroidism caused by the multiple endocrine neoplasia
(MEN) type 1 syndrome [65]. Moreover, it is important to
review prior medical records, radiographs and other investigations, such as the results of plasma and urinary biochemistry, to aid diagnosis and prognostication [3]. Physical
assessment should include: measurement of body proportions, limb lengths and head circumference; an examination
of the spine for scoliosis or kyphosis; and joint hypermobility
with a determination of the Beighton score [66]. Physical
examination can show a variety of ﬁndings for diagnosis,
e.g. blue or grey sclerae found in OI; café-au-lait spots or other
pigmentary cutaneous lesions that are associated with disorders of FGF-23 excess such as MAS or the epidermal nevus
Br J Clin Pharmacol (2019) 85 1147–1160
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syndrome; angioﬁbromas or collagenomas that may be associated with MEN type 1; premature loss of deciduous teeth
that occurs in hypophosphatasia; hallux valgus which is
found in ﬁbrodysplasia ossiﬁcans progressiva; alopecia that
occurs in vitamin D-dependent rickets, type 2; brachydactyly
which is found in PHP1a and PPHP; syndactyly that occurs in
sclerosteosis types 1 and 2; torus palatinus which is found in
disorders of high bone mass due to LRP5 or LRP6 mutations;
or numerous surgical scars which may reveal a past medical
history of surgical treatments to remove endocrine tumours
associated with the MEN syndromes [10, 20, 36, 39, 48, 50,
65, 67–69]. For some genetic bone diseases, a constellation
of physical features indicates the category for diagnosis;
e.g. rickets featuring craniotabes at birth and soon after a rachitic rosary (enlargement of the costochondral junctions)
appearing during the ﬁrst year of life [10]. Childhood-onset
rickets causes bowed legs, short stature, ﬂared wrists and
ankles from metaphyseal widening [10]. Knock-knee deformities may occur instead of bowed legs if the rachitic disturbance occurs during the adolescent growth spurt [3]. In
adults, skeletal deformation originating from metabolic
bone disorders in childhood can cause substantial morbidity. Bowing of the lower limbs predisposes to osteoarthritis,
especially affecting the knees. Without a complete physical
examination, these important problems may go unnoticed.

Family history
Assessment of the family history is essential for establishing
the mode of inheritance of monogenic metabolic bone diseases, and medical records from living or deceased affected
family members may establish the diagnosis, guide prognostication, and indicate a safe and effective treatment [3]. In autosomal dominant disease, the affected person often has one
affected parent, and the disease occurs in both sexes and is
transmitted by either the father or mother. In autosomal recessive diseases, which can affect both sexes, the proband is
born to parents who are usually asymptomatic ‘carriers’ and
sometimes related (i.e. consanguineous). In X-linked recessive diseases, usually only males are affected, parents are unaffected yet the mother is an asymptomatic carrier, and
there is no male-to-male transmission. In X-linked dominant
diseases, both males and females can be affected, although
the females are often more mildly and variably affected than
males, and 50% of offspring (girls and boys) from an affected
woman will have the disease, and 100% of the daughters but
0% of sons of an affected man will have the disease. In
Y-linked diseases, only males are affected and, unless
representing a sporadic case, they have an affected father
(patrilineal inheritance) and all sons of an affected male will
have the disease. Mitochondrial inherited disorders (nonMendelian) can affect both sexes. However, these disorders
are only transmitted by an affected mother (matrilineal inheritance) in her egg mitochondrial DNA, and not through
the paternal line in the sperm, as the small volume of sperm
precludes them from contributing mitochondria to the zygote [3]. These patterns of inheritance may be complicated
by: non-penetrance or variable expression in autosomal dominant disorders (e.g. in MEN1) [65]; imprinting whereby expression of an autosomal dominant disorder is conditioned
by whether it is maternally or paternally transmitted
1152
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(e.g. PHP1a versus PPHP) [39]; anticipation, whereby some
dominant disorders become more severe (or have earlier
onset) in successive generations; pseudo-dominant inheritance of autosomal recessive disorders reﬂecting repeated
consanguineous marriages in successive generations; and
mosaicism in which an individual has two or more populations of cells with different genotypes because of postzygotic mutations during their development from a single
fertilized egg (e.g. MAS). In the special circumstance of
germline mosaicism within eggs or sperm arising from somatic mutation during gametogenesis, there may be confusion about the diagnosis and recurrence risk because of
seemingly unaffected parents having multiple affected offspring that would be consistent with autosomal recessive
inheritance, but actually reﬂects an autosomal dominant
disorder (e.g. OI type II) [70]. Hence, these inheritance
patterns, which can help to diagnose a genetic disorder
and identify individuals at risk, can come from a detailed
family history [3].

Clinical utility of genetic investigations
Establishing the genetic basis of a metabolic bone disease
may aid diagnosis, treatment and prognostication; identify
the need for screening of associated clinical features not initially apparent; enable appropriate genetic counselling and
testing of ﬁrst-degree asymptomatic relatives; and facilitate
preconception and/or prenatal genetic evaluation (Figure 2).
Genetic testing may also aid risk proﬁling. For example,
osteoporosis-associated SNPs have been reported to predict
fracture risk in patients taking bisphosphonates [71], and
other studies have identiﬁed potential genetic markers of
bisphosphonate-induced osteonecrosis of the jaw [72].
For patients presenting with a likely genetic metabolic
bone disease, several factors require consideration before organizing genetic testing (Figure 2). These include the phenotype of the patient, the likely mode of inheritance, the
potential genetic aetiology [e.g., aneuploidy, copy number
variation (CNV), or single gene defect], and availability of additional pedigree members (Figure 2). For example, DNA sequencing of ‘trios’ (i.e. both parents and the affected
proband) may facilitate the identiﬁcation of compound
heterozygous or de novo mutations [73]. Selecting the most
appropriate genetic test will increase the likelihood of achieving a genetic diagnosis. For example, direct DNA sequencing
methods which detect nucleotide abnormalities (e.g. substitutions, micro-deletions and micro-insertions) that cause
most monogenic metabolic bone disorders frequently do
not detect whole or partial gene deletions that are associated with some monogenic syndromes, and are also not
optimal for identifying large chromosomal abnormalities
(e.g. 22q11.2 microdeletion in DiGeorge syndrome), whose
detection requires alternative approaches (Figure 2 and
Table 2) [74]. For other monogenic disorders, it is also important to consider analysis of a panel of genes if genetic
heterogeneity is likely (e.g. in FHH or OI) [9, 20]. Thus, it
is important to emphasize that genetic testing which fails
to identify an abnormality does not exclude a genetic disease, but rather may reﬂect: an alternative genetic aetiology
to the one being tested; limitations of the employed genetic methodology (i.e. inadequate resolution or coverage);

Genetic approaches to metabolic bone diseases

Figure 2
Flowchart outlining considerations for genetic testing in patients with metabolic bone disease
Br J Clin Pharmacol (2019) 85 1147–1160
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Table 2
Examples of genetic tests, their molecular resolution and utility

Genetic test

Resolution

Abnormalities detected

Additional notes

Detection of chromosomal abnormalities including CNVs
Karyotype: G-banding
(trypsin-Giemsa staining)

5–10 Mb

Fluorescence in situ
hybridization (FISH)

50 kb–2 Mb (dependent on
size of probes employed)

Multiplex-ligation probe
ampliﬁcation

Probe dependent
50–70 nucleotides

Aneuploidy

Limited resolution

Large chromosomal deletions,
duplications, translocations,
inversions, insertions

Requirement to study many cells
to detect mosaicism

Structural chromosomal
abnormalities (e.g.
microdeletions, translocations)

Labour-intensive

Copy number variations (CNVs)
including (partial) gene deletions
or duplications

Low cost, technically simple method

Single exon deletion or
duplication possible
Array comparative
genomic hybridization
(aCGH)

10 kb (high resolution)

Single nucleotide
polymorphism
(SNP) array

Low resolution limits its use
Unsuitable where unknown
genetic aetiology
Simultaneous evaluation of multiple
genomic regions
Not suitable for genome-wide approaches
Not suitable for analysis of single cells

Genome-wide copy number
variations (CNVs)

Inability to detect balanced translocations

~50–400 kb

Genome-wide detection of SNP
genotypes

Inability to detect balanced translocation

(Dependent on probe set)

Copy Number Variations (CNVs)

Useful for detection of low level mosaicism

1 Mb (low resolution)

Useful for detection of low level mosaicism

(Dependent on probes set)

Detection of copy number neutral regions
or absence of heterozygosity (i.e. due to
uniparental disomy)
Detection of monogenic disorders (and CNVs)
First generation
sequencing (Sanger)
Single gene test

Single nucleotide

Single nucleotide variants (SNVs)

Relative high cost/base

(exonic regions and intron/exon
boundaries of candidate gene)

Small insertions or deletions (‘indels’)

May miss large deletions/duplications

Single nucleotide

Single nucleotide variants (SNVs)

May lack complete coverage of exomic
regions (may require Sanger sequencing
to ﬁll in ‘gaps’)

(exonic regions and intron/exon
boundaries of candidate genes)

Small insertions or deletions (‘indels’)

Increased likelihood of identifying variants
of uncertain signiﬁcance (VUS) as number
of genes increases

Single nucleotide

Single nucleotide variants (SNVs)

Not all exons may be covered/captured

(all exonic regions and
intron/exon boundaries)

Small insertions or deletions (‘indels’)

Difﬁculties with GC-rich regions and
presence of homologous regions/
pseudogenes

Unsuitable where unknown genetic
aetiology

Next generation
sequencing
Disease-targeted
gene panels

Unsuitable where unknown genetic aetiology
Whole exome
sequencing (WES)

Copy number variations (CNVs)

Small indels may not be captured
Bioinformatic expertise required for
data analysis
High likelihood of incidental ﬁndings
and VUSs
Detection of CNVs requires additional
data analysis (i.e. loss of heterozygosity
mapping across exonic regions)
Suitable for disease associated genediscovery

(continues)
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Table 2
(Continued)

Genetic test
Whole genome
sequencing (WGS)

Resolution

Abnormalities detected

Additional notes

Single nucleotide

Single nucleotide variants (SNVs)

Relative high cost

Small insertions or deletions
(‘indels’)

Large data sets generated and complex
data analysis requiring bioinformatic
expertise

Copy Number Variations (CNVs)

High likelihood of incidental ﬁndings
and VUSs

(Translocations/rearrangements)

CNV analysis possible but may present
speciﬁc challenges
Suitable for disease associated
gene-discovery

CNVs, copy number variants; FISH, ﬂuorescence in-situ hybridization; LOH, loss of heterozygosity; WES, whole exome sequencing; WGS, whole
genome sequencing. Adapted from Thakker, Whyte, Eisman, Igarashi, eds., Genetics of Bone Biology and Skeletal Disease, 2nd ed. Amsterdam:
Academic Press, 2018: 14 [3]

or incorrect assumptions regarding the clinical phenotype
or mode of inheritance [3]. As a consequence, it may be
necessary to undertake sequential or simultaneous genetic
tests to ensure a complete evaluation, although such testing may be limited by cost and local availability.

Types of genetic tests available to the clinician
Cytogenetic and molecular cytogenetic analyses. Karyotyping
represents the initial test for major chromosomal
abnormalities including aneuploidy or large insertions,
deletions,
duplications,
inversions
or
reciprocal
translocations, but has a resolution limited to ~5–10 Mb of
DNA (Table 2) [74, 75]. It retains an important place in the
diagnosis of Turner and Klinefelter syndrome, each of
which may manifest a form of osteoporosis [76, 77].
Fluorescence in-situ hybridization (FISH) employs DNA
probes that hybridize to speciﬁc target regions, which allow
the detection of speciﬁc chromosomal deletions,
duplications, translocations or inversions (Table 2). The
utility of FISH is limited to detecting abnormalities
involving pre-determined genomic regions (e.g. detection of
22q11.2 deletion in DiGeorge syndrome). Multiplex-ligation
dependent probe ampliﬁcation (MLPA) detects complete or
partial gene deletions by using a pool of custom-designed
probes to amplify speciﬁc genomic regions of interest
(Table 2). MLPA is used in the diagnostic evaluation of
monogenic disorders associated with such genetic alterations
(e.g. MEN1) [78]. Modiﬁcations of the MLPA technique may
also be used. For example, in establishing the diagnosis of
pseudohypoparathyroidism type 1b (PHP1b), methylationspeciﬁc MLPA (MS-MLPA) may be employed to detect genetic
(e.g. deletions) or epigenetic (e.g. altered patterns of
methylation) abnormalities within the differentially
methylated regions (DMRs) of the GNAS locus, although
alternate methods such as CpG bisulphite pyrosequencing
are frequently used to conﬁrm the presence of speciﬁc
methylation defects [79]. Microarray-comparative genomic
hybridization (aCGH) is undertaken for the genome-wide
detection of small chromosomal abnormalities (e.g. CNVs)
(Table 2) and is increasingly used as a ﬁrst-line investigation
for patients with multiple congenital abnormalities, which

include skeletal manifestations and/or neurodevelopmental
delay [80, 81]. However, it is important to note that all
individuals harbour many small CNVs without discernible
adverse impact on health, whilst several potentially
pathogenic CNVs do not cause disease in all individuals
(i.e. reduced penetrance). Finally, SNP arrays may detect
CNVs as well as facilitating genome-wide genotyping
(Table 2). For example, deletions spanning several adjacent
SNPs included on the array may reveal loss of heterozygosity
(LOH), whilst copy number gains (e.g. duplication) may be
indicated by increased numbers of different genotypes [74].
SNP arrays may also help localize recessive disorders in
the offspring of consanguineous parents by facilitating
homozygosity mapping [82], whilst regions of LOH can also
indicate uniparental isodisomy, which may be relevant to
the diagnosis of imprinting disorders such as PHP1b [83, 84].

DNA sequence analysis
Sanger sequencing remains the gold standard for detecting
DNA sequence variants due to the high accuracy of the DNA
polymerase (i.e. base accuracy of >99.99%) employed during
DNA ampliﬁcation [41, 85]. However, it remains labour intensive and is typically reserved for disorders with low genetic
heterogeneity (e.g. single- or pauci-gene disorders), an example being hypophosphatasia caused only by TNSALP/ALPL
mutations [86]. Single-gene testing by Sanger sequencing is
increasingly being replaced by next-generation sequencing
(NGS) approaches, which facilitates the simultaneous sequencing of large amounts of genetic material. Such NGS
methodology has provided a paradigm shift in the investigation and diagnosis of genetic disease. Currently, the three
most widely employed uses of NGS are whole genome sequencing (WGS), whole exome sequencing (WES), and
disease-targeted gene panel sequencing (Table 2). WGS determines the DNA sequence of the entire genome including coding and non-coding regions, and can identify SNVs, small
insertions or deletions (‘indels’) and CNVs [3]. In contrast,
WES analyses the 1–2% of the genome that encodes the
~20 000 protein-coding genes (i.e. the ‘exome’), which are expected to harbour most disease-associated mutations [3]. WES
has been the mainstay of highly successful disease-gene
Br J Clin Pharmacol (2019) 85 1147–1160
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discovery studies over the past decade, resulting in the identiﬁcation of several genes responsible for metabolic bone disorders (e.g. WNT1 mutations as causes of osteoporosis and OI
[19]; SFRP4 mutations in Pyle’s disease [54]; AP2σ mutations
in FHH type 3 [33]; PLS3 mutations in X-linked osteoporosis
[18]; BMP1 mutations causing increased BMD and recurrent
fractures [87]; and CYP3A4 mutations in vitamin Ddependent rickets, type 3 [88]). Disease-targeted sequencing
represents the most widely utilized NGS method in clinical
practice, as it can be designed to simultaneously analyse large
collections of genes (e.g. <10 to >150 genes) associated with
a speciﬁc disorder [41, 84, 89]. Such NGS disease-targeted
panels have been established for genetically heterogeneous
disorders including OI and other skeletal disorders, as well
as for hypophosphataemic rickets and calcium-sensing disorders [90–92].

Genetic tests to detect mosaicism
Some metabolic bone disorders only manifest as somatic
mosaicism (e.g. GNAS mutations in MAS) [67]. However,
other conditions (e.g. OI type II) may also rarely occur as
germline mosaicism, arising from somatic mutation during
gametogenesis, and may cause diagnostic confusion. In this
setting, apparently unaffected parents (with one carrying
the mutation limited to their gametes) may give rise to more
than one affected child, suggesting possible autosomal recessive inheritance, in contrast to the underlying autosomal
dominant inheritance pattern [93]. Detection of mosaicism
has been enhanced by improved genome-wide testing
strategies (e.g. aCGH, SNP arrays, droplet digital PCR and
NGS approaches), which can provide sensitive methods for
the detection of low-level mosaicism (e.g. 5% for SNP array)
[70, 94, 95]. However, choosing the optimal test depends
on the clinical phenotype, the type of mutation suspected
(e.g. SNV, CNV, aneuploidy), the likely extent of mosaicism,
and its tissue distribution. Typically, circulating lymphocyte
DNA will sufﬁce, but analysis of other affected tissues may
be required (e.g. ﬁbroblasts or bone) [96, 97].

Genetic tests for prenatal diagnosis
Prenatal genetic testing may be undertaken at preimplantation or prenatal stages, and has been used to detect
severe skeletal disorders such as perinatal lethal OI [98]. Preimplantation genetic diagnosis (PGD) uses a single cell taken
from the developing embryo several days after in vitro fertilization (IVF) to detect chromosomal abnormalities or single
gene defects, thereby allowing selection of the unaffected embryos for implantation [99]. In contrast, prenatal genetic testing is used once pregnancy is established to identify fetuses at
risk of genetic disease [99]. Typically, this involves invasive
methods such as chorionic villous sampling (CVS) or amniocentesis to obtain cells for genetic evaluation [99]. This may
include karyotyping for the detection of aneuploidy, FISH or
aCGH to identify smaller chromosomal abnormalities or
DNA sequencing to identify single gene defects associated
with monogenic disease. Recent progress in the detection of
cell-free circulating fetal DNA in the maternal circulation
(e.g. after ~10 weeks gestation) now offers the potential for
non-invasive prenatal genetic diagnosis (NIPD) and/or testing (NIPT) [100]. Thus, a maternal blood sample may allow
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screening for aneuploidy and fetal sex determination, which
is important for X-linked disorders, and may also be used to
detect monogenic disorders; however, this is limited to paternally inherited mutations or those arising de novo, as the
sample may contain maternal cell-free DNA, and hence the
detected abnormality cannot be reliably assigned to the fetus
as the methodology cannot distinguish between fetal and
‘contaminating’ maternal DNA in the sample [100].

Data interpretation and incidental findings
The advent of high-content genetic testing employing NGS
approaches has revolutionized the investigation and diagnosis of genetic disease. However, such approaches may also
present clinical and ethical challenges [101]. For example,
the simultaneous sequencing of large numbers of genes
(e.g. disease-targeted gene panels, WES and WGS) inevitably
identiﬁes variants of uncertain signiﬁcance (VUS), whose
relevance to the clinical phenotype is ambiguous [102, 103].
Indeed, the methods employed to assess variant effects are
frequently imprecise leading to inaccurate interpretation,
although the provision of recent large-scale population level
sequence databases facilitates improved estimates of variant
pathogenicity and penetrance [104, 105]. In addition,
high-content genetic testing may identify clinically relevant
genetic abnormalities unrelated to the phenotype under investigation [i.e. incidental ﬁndings (IFs)] and these may have
important health implications for the patient and their
family. Hence, the possibility of identifying ambiguous or
incidental results should be part of the informed consent
prior to genetic testing (Figure 2).

Conclusion
Many metabolic bone diseases have a genetic basis, which
may be a germline single gene abnormality (i.e. a monogenic
or Mendelian disorder), a somatic single gene defect (i.e. a
post-zygotic mosaic disorder), or involve several genetic variants (i.e. oligogenic or polygenic disorders). Recognition of
these heritable disorders is clinically important, as it can facilitate relevant and timely investigation and treatment for the
patients and families. Recent advances in genetics and DNA
sequencing methods have resulted in new ways to detect genetic abnormalities. Therefore, it is increasingly important
for the clinician to gain an appreciation of these complex
genetic tests and to combine this with the fundamental skills
of history taking and physical examination to ensure they are
used for the beneﬁt of patients.

Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY [111], and are
permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [112–115].
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